Safety pharmacology of acute MDMA administration in healthy subjects
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is being investigated in MDMA-assisted psychotherapy. The present study characterized the safety pharmacology of single-dose administrations of MDMA (75 or 125 mg) using data from nine double-blind, placebo-controlled, crossover studies performed in the same laboratory in a total of 166 healthy subjects. The duration of the subjective effects was 4.2 ± 1.3 h (range: 1.4–8.2 h). The 125 mg dose of MDMA produced greater ‘good drug effect’ ratings than 75 mg. MDMA produced moderate and transient ‘bad drug effect’ ratings, which were greater in women than in men. MDMA increased systolic blood pressure to >160 mmHg, heart rate >100 beats/min, and body temperature >38°C in 33%, 29% and 19% of the subjects, respectively. These proportions of subjects with hypertension (>160 mmHg), tachycardia, and body temperature >38°C were all significantly greater after 125 mg MDMA compared with the 75 mg dose. Acute and subacute adverse effects of MDMA as assessed by the List of Complaints were dose-dependent and more frequent in females. MDMA did not affect liver or kidney function at EOS 29 ± 22 days after use. No serious adverse events occurred. In conclusion, MDMA produced predominantly acute positive subjective drug effects. Bad subjective drug effects and other adverse effects were significantly more common in women. MDMA administration was overall safe in physically and psychiatrically healthy subjects and in a medical setting. However, the risks of MDMA are likely higher in patients with cardiovascular disease and remain to be investigated in patients with psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 1×
“In contrast to MDMA, acute pharmacological tolerance was not observed with lysergic acid diethylamide (LSD), which is also investigated in substance-assisted psychotherapy (Gasser et al., 2014), and the effect duration of LSD was shown to be dose-dependent (Dolder et al.”
BackgroundMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674 · cited 10×
“Male and female subjects were treated with the same 125 mg dose irrespective of body weight in the clinical studies in patients (Mithoefer et al., 2010; Oehen et al., 2013).”
BackgroundMethodResultInfluentialVollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448 · cited 1×
“We included only psychiatrically healthy subjects and the risks of using MDMA in persons with psychiatric disorders may be different (Greer and Tolbert, 1986; Parrott, 2007; Vollenweider et al., 1998) and also need to be investigated.”
BackgroundSelf-citationSubjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413 · cited 2×
“We included only psychiatrically healthy subjects and the risks of using MDMA in persons with psychiatric disorders may be different (Greer and Tolbert, 1986; Parrott, 2007; Vollenweider et al., 1998) and also need to be investigated.”
BackgroundGender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360 · cited 8×
“Depressed mood, including emotional irritability, lack of energy, brooding and bad dreams, has previously been reported in up to one-third of subjects, lasting up to three days in some subjects (Liechti et al., 2001).”
BackgroundResultInfluentialSelf-citationMDMA enhances emotional empathy and prosocial behavior
Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H., Quednow, B. B., & Liechti, M. E. (2014) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nst161 · Cited by 356
Self-citationBedi, G., Hyman, D., & de Wit, H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.003 · Cited by 247
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.82 · Cited by 247
Self-citationKamilar-Britt, P., & Bedi, G. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.08.016 · Cited by 163
Differential effects of MDMA and methylphenidate on social cognition
Schmid, Y., Hysek, C. M., Simmler, L. D., Crockett, M. J., Quednow, B. B., & Liechti, M. E. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114542454 · Cited by 155 · cited 8×
“Other stimulant drugs, such as methamphetamine, D-amphetamine and methylphenidate, produced comparable cardiovascular stimulation to MDMA when administered as single oral doses (Bershad et al., 2015; Brauer et al., 1996; Hysek et al., 2014b; Kirkpatrick et al., 2012; Martin et al., 1971; Schmid et al., 2014; Wardle an…”
BackgroundMethodResultInfluentialSelf-citation
Research works printed but not linked: 70
- 10.1177/0269881116642542 · DOI · Paper page
- Atayan Y, 2015, Acta Gastroenterol Belg, 78, 53
- 10.1097/00063110-200312000-00013 · DOI
- 10.1097/JCP.0000000000000314 · DOI · Paper page
- 10.1097/00004714-199602000-00012 · DOI · Paper page
- 10.1007/s00213-011-2529-4 · DOI
- 10.1177/0269881116650388 · DOI
- 10.1016/0031-9384(95)00136-7 · DOI
- 10.1111/j.1749-6632.2000.tb05199.x · DOI · Paper page
- 10.1016/j.neuropharm.2014.03.008 · DOI
- 10.1002/hup.2389 · DOI · Paper page
- 10.1093/ijnp/pyv072 · DOI · Paper page
- 10.1177/0269881108100020 · DOI
- 10.1038/clpt.2009.62 · DOI · Paper page
- 10.1136/gut.38.3.454 · DOI · Paper page
- 10.1124/jpet.107.129056 · DOI
- 10.1007/s00213-004-1789-7 · DOI · Paper page
- 10.1016/j.euroneuro.2015.05.007 · DOI
- 10.1007/s00213-005-0149-6 · DOI
- Grunau BE, 2010, Canadian J Emerg Med, 12, 435, 10.1017/S1481803500012598 · DOI
- 10.1177/0960327110370984 · DOI
- 10.1093/qjmed/95.7.431 · DOI
- 10.1177/0269881108094650 · DOI · Paper page
- 10.1016/0140-6736(92)91469-O · DOI · Paper page
- 10.1007/s00213-012-2761-6 · DOI
- 10.1124/jpet.111.188425 · DOI
- 10.1097/JCP.0b013e3182979d32 · DOI · Paper page
- 10.1111/j.1476-5381.2012.01936.x · DOI · Paper page
- 10.1038/clpt.2011.78 · DOI · Paper page
- 10.1371/journal.pone.0036476 · DOI · Paper page
- 10.1017/S1461145713001132 · DOI · Paper page
- 10.1007/s00213-014-3528-z · DOI · Paper page
- 10.1007/s00213-011-2383-4 · DOI · Paper page
- 10.1097/JCP.0b013e31817ef470 · DOI · Paper page
- 10.1097/FTD.0b013e3181684fa0 · DOI · Paper page
- 10.1126/science.345.6192.22 · DOI
- 10.1371/journal.pone.0149438 · DOI
- 10.4161/23328940.2014.955433 · DOI
- Liechti ME, 2005, Swiss Med Wkly, 135, 652
- 10.1016/j.euroneuro.2014.05.008 · DOI
- 10.1038/ajg.2014.399 · DOI
- 10.1002/cpt1971122part1245 · DOI · Paper page
- 10.1016/S2215-0366(15)00576-3 · DOI · Paper page
- 10.1016/j.neubiorev.2015.12.010 · DOI · Paper page
- 10.1177/0269881112464827 · DOI · Paper page
- 10.1371/journal.pone.0047599 · DOI · Paper page
- 10.1002/hup.2318 · DOI · Paper page
- 10.1016/j.neubiorev.2013.04.016 · DOI
- 10.1080/02791072.2014.873690 · DOI · Paper page
- 10.1007/s00213-011-2184-9 · DOI
- 10.1007/s00213-012-2894-7 · DOI
- 10.1016/S0140-6736(01)06888-X · DOI · Paper page
- 10.3310/hta13060 · DOI · Paper page
- 10.1016/j.annemergmed.2006.09.018 · DOI
- 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3 · DOI · Paper page
- 10.1016/j.biopsych.2014.11.015 · DOI · Paper page
- 10.1124/jpet.114.222356 · DOI
- 10.1097/FPC.0000000000000231 · DOI · Paper page
- 10.1192/bjp.bp.114.152751 · DOI · Paper page
- 10.1111/j.1476-5381.2012.02145.x · DOI · Paper page
- 10.1210/jc.2011-1143 · DOI · Paper page
- 10.1371/journal.pone.0040187 · DOI · Paper page
- 10.1007/s00213-001-0995-9 · DOI
- 10.1016/j.euroneuro.2017.01.008 · DOI
- 10.1038/sj.npp.1395197 · DOI · Paper page
- 10.1007/s00213-011-2498-7 · DOI · Paper page
- 10.1007/s00213-012-2708-y · DOI · Paper page
- 10.1093/scan/nsu035 · DOI · Paper page
- Wood DM, 2016, Hospital Emergency Presentations and Acute Drug Toxicity in Europe: Update from the Euro-DEN Plus Research Group and the EMCDDA
- Zerssen DV, 1976, Die Beschwerden-Liste. Münchener Informationssystem
Cited by
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004
MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial
Mitchell, J. M., Ot’alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02565-4 · Cited by 455
Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5010-9 · Cited by 280
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Self-citationDistinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Self-citation
Metadata
- Authors
- Vizeli, P., & Liechti, M. E.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-02-21
- Volume
- 31
- Issue
- 5
- Pages
- 576-588
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2590375860
- Cited by
- 145
- References
- 20
- FWCI
- 14.54
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Funders
- Swiss National Science Foundation (323230_126231, 32323B_144996, and 320030_149493 to)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety pharmacology of acute MDMA administration in healthy subjects. https://app.cochat.ai/papers/10.1177/0269881117691569
- The paper
- Vizeli, P., & Liechti, M. E. (2017). Safety pharmacology of acute MDMA administration in healthy subjects. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117691569
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.